1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
(
- Contribution to journal › Article
- 2023
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
- 2022
-
Mark
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
(
- Contribution to journal › Article
- 2020
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register
(
- Contribution to journal › Article